Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 28781 [2011-12194]

Download as PDF Federal Register / Vol. 76, No. 96 / Wednesday, May 18, 2011 / Notices Reason: Failed to maintain valid bonds. DEPARTMENT OF HEALTH AND HUMAN SERVICES Sandra L. Kusumoto, Director, Bureau of Certification and Licensing. Independent Scientific Peer Review Panel Report: Evaluation of the Validation Status of an In Vitro Estrogen Receptor Transcriptional Activation Test Method for Endocrine Disruptor Chemical Screening: Notice of Availability and Request for Public Comments [FR Doc. 2011–12222 Filed 5–17–11; 8:45 am] BILLING CODE 6730–01–P FEDERAL RESERVE SYSTEM srobinson on DSKHWCL6B1PROD with NOTICES The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 13, 2011. A. Federal Reserve Bank of San Francisco (Kenneth Binning, Vice President, Applications and Enforcement) 101 Market Street, San Francisco, California 94105–1579: 1. BankGuam Holding Company, to become a bank holding company by acquiring 100 percent of Bank of Guam, both of Hagatna, Guam, and also elects to become a financial holding company. Board of Governors of the Federal Reserve System, May 13, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–12194 Filed 5–17–11; 8:45 am] Division of the National Toxicology Program (DNTP), National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). ACTION: Notice of availability and request for comments. AGENCY: Formations of, Acquisitions by, and Mergers of Bank Holding Companies The NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), on behalf of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), convened an independent international scientific peer review panel (hereafter, Panel) on March 29–30, 2011, to evaluate the validation status of the LUMI–CELL® (BG1Luc ER TA) test method, an in vitro transcriptional activation (TA) assay used to identify chemicals that can interact with human estrogen receptors (ERs). The Panel report is now available on the NICEATM–ICCVAM Web site at: http:// iccvam.niehs.nih.gov/docs/endo_docs/ EDPRPRept2011.pdf or by contacting NICEATM (see ADDRESSES). The report contains (1) the Panel’s evaluation of the validation status of the test method and (2) the Panel’s comments on the draft ICCVAM test method recommendations. NICEATM invites public comment on the Panel report. DATES: Written comments on the Panel report should be received by July 5, 2011. SUMMARY: NICEATM prefers that comments be submitted electronically by e-mail to niceatm@niehs.nih.gov. Comments can also be submitted via the NICEATM–ICCVAM Web site at http:// iccvam.niehs.nih.gov/contact/FR_ pubcomment.htm. Written comments can be sent by mail or fax to Dr. Warren Casey, Deputy Director, NICEATM, NIEHS, P.O. Box 12233, Mail Stop: K2– 16, Research Triangle Park, NC 27709; (fax) 919–541–0947. Courier address: NIEHS, NICEATM, 530 Davis Drive, Room 2035, Durham, NC 27713. FOR FURTHER INFORMATION CONTACT: Dr. Warren Casey: (telephone) 919–316– 4729, (fax) 919–541–0947, (e-mail) niceatm@niehs.nih.gov. ADDRESSES: BILLING CODE 6210–01–P VerDate Mar<15>2010 16:31 May 17, 2011 Jkt 223001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 28781 SUPPLEMENTARY INFORMATION: Background In January 2011, NICEATM announced the convening of an independent scientific peer review panel to review and comment on the draft background review document (BRD) summarizing available data, reliability and accuracy of the BG1Luc ER TA test method, the draft recommendations, as well as the availability of the draft documents for public comment (76 FR 4113). The Panel met in public session on March 29–30, 2011, at the Natcher Conference Center in Bethesda, MD. The Panel reviewed the draft ICCVAM BRD for completeness, errors, and omissions of any existing relevant data or information. The Panel also evaluated the information in the draft documents to determine the extent to which each of the applicable criteria for validation and acceptance of toxicological test methods (ICCVAM, 2003a) had been appropriately addressed. The Panel then considered the ICCVAM draft recommendations and commented on the extent that the recommendations were supported by the information provided in the draft BRD. In January 2004, Xenobiotic Detection Systems, Inc. (XDS, Durham, NC) nominated their LUMI–CELL® BG1Luc ER TA test method for an interlaboratory validation study. This method uses BG–1 cells, a human ovarian carcinoma cell line that is stably transfected with an estrogen-responsive luciferase reporter gene to measure whether and to what extent a substance induces or inhibits TA activity via ER mediated pathways (Denison and HeathPagliuso, 1998). Included in the nomination package were test results from XDS for 56 of the 78 ICCVAM reference substances for agonist activity and 16 of the 78 ICCVAM reference substances for antagonist activity. These studies were funded primarily by an NIEHS Small Business Innovation Research (SBIR) grant (SBIR43ES010533–01). In accordance with the ICCVAM nomination process, NICEATM conducted a preliminary evaluation of the nomination package to determine the extent to which it addressed the ICCVAM prioritization criteria and adherence to the ICCVAM recommendations for the standardization and validation of in vitro endocrine disruptor test methods (ICCVAM, 2003b). ICCVAM and the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) recommended that the BG1Luc ER TA test method should be E:\FR\FM\18MYN1.SGM 18MYN1

Agencies

[Federal Register Volume 76, Number 96 (Wednesday, May 18, 2011)]
[Notices]
[Page 28781]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-12194]


=======================================================================
-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM


Formations of, Acquisitions by, and Mergers of Bank Holding 
Companies

    The companies listed in this notice have applied to the Board for 
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 
1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other 
applicable statutes and regulations to become a bank holding company 
and/or to acquire the assets or the ownership of, control of, or the 
power to vote shares of a bank or bank holding company and all of the 
banks and nonbanking companies owned by the bank holding company, 
including the companies listed below.
    The applications listed below, as well as other related filings 
required by the Board, are available for immediate inspection at the 
Federal Reserve Bank indicated. The application also will be available 
for inspection at the offices of the Board of Governors. Interested 
persons may express their views in writing on the standards enumerated 
in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the 
acquisition of a nonbanking company, the review also includes whether 
the acquisition of the nonbanking company complies with the standards 
in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, 
nonbanking activities will be conducted throughout the United States.
    Unless otherwise noted, comments regarding each of these 
applications must be received at the Reserve Bank indicated or the 
offices of the Board of Governors not later than June 13, 2011.
    A. Federal Reserve Bank of San Francisco (Kenneth Binning, Vice 
President, Applications and Enforcement) 101 Market Street, San 
Francisco, California 94105-1579:
    1. BankGuam Holding Company, to become a bank holding company by 
acquiring 100 percent of Bank of Guam, both of Hagatna, Guam, and also 
elects to become a financial holding company.

    Board of Governors of the Federal Reserve System, May 13, 2011.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2011-12194 Filed 5-17-11; 8:45 am]
BILLING CODE 6210-01-P